Access to anti-retroviral drugs, female in Ecuador

Ecuador: Access to anti-retroviral drugs, female was 75.0% in 2024. ◆ Volatile

Latest (2024)
75.0%
Change on year
up 1.4%
World rank
67th
of 141 countries
All-time high
75.0%
in 2024
All-time low
2.0%
in 2000
Years of data
25
2000–2024

Access to anti-retroviral drugs, female in Ecuador, 2000–2024

0204060802000201220242000: 2 %2001: 2 %2002: 2 %2003: 2 %2004: 3 %2005: 4 %2006: 5 %2007: 8 %2008: 11 %2009: 14 %2010: 17 %2011: 20 %2012: 23 %2013: 33 %2014: 39 %2015: 44 %2016: 43 %2017: 49 %2018: 55 %2019: 64 %2020: 70 %2021: 69 %2022: 70 %2023: 74 %2024: 75 %

Source: UNAIDS estimates. Measured in %.

Analysis

Ecuador recorded 75.0% for access to anti-retroviral drugs, female in 2024. That is the highest value across all 25 years on record.

The figure is up 1.4% on the previous year and up 92.3% over ten years.

Over the whole period, access to anti-retroviral drugs, female in Ecuador peaked at 75.0% in 2024 and was at its lowest, 2.0%, in 2000.

Ecuador ranks 67th of 141 countries on this measure, in the middle of the range.

The series is highly variable year to year, so single readings are best treated with caution.

Access to anti-retroviral drugs, female in Ecuador, year by year

Annual values for Access to anti-retroviral drugs, female (%) in Ecuador, 2000 to 2024.
Year % Change
2000 2.0%
2001 2.0% +0.0%
2002 2.0% +0.0%
2003 2.0% +0.0%
2004 3.0% +50.0%
2005 4.0% +33.3%
2006 5.0% +25.0%
2007 8.0% +60.0%
2008 11.0% +37.5%
2009 14.0% +27.3%
2010 17.0% +21.4%
2011 20.0% +17.6%
2012 23.0% +15.0%
2013 33.0% +43.5%
2014 39.0% +18.2%
2015 44.0% +12.8%
2016 43.0% -2.3%
2017 49.0% +14.0%
2018 55.0% +12.2%
2019 64.0% +16.4%
2020 70.0% +9.4%
2021 69.0% -1.4%
2022 70.0% +1.4%
2023 74.0% +5.7%
2024 75.0% +1.4%

Averages by decade

DecadeAverage LowestHighest Years
2000s 5.3% 2.0% 14.0% 10
2010s 38.7% 17.0% 64.0% 10
2020s 71.6% 69.0% 75.0% 5

Countries ranked near Ecuador

  1. 64 Bahamas 76.0% compare
  2. 64 Honduras 76.0% compare
  3. 64 Oman 76.0% compare
  4. 67 Guyana 75.0% compare
  5. 69 Comoros 74.0% compare
  6. 69 El Salvador 74.0% compare

See the full ranking of 160 places →

More gender data for Ecuador

All data for Ecuador →

Frequently asked questions

What is access to anti-retroviral drugs, female in Ecuador?
Access to anti-retroviral drugs, female in Ecuador was 75.0% in 2024, according to UNAIDS estimates.
What is the highest access to anti-retroviral drugs, female recorded in Ecuador?
The highest recorded value was 75.0% in 2024.
What is the lowest access to anti-retroviral drugs, female recorded in Ecuador?
The lowest recorded value was 2.0% in 2000.
How does Ecuador rank for access to anti-retroviral drugs, female?
Ecuador ranks 67th out of 141 countries with data for 2024.
Is access to anti-retroviral drugs, female rising or falling in Ecuador?
Over the last ten years it is up 92.3%. The long-run trend across the full record is volatile.
Where does this Ecuador data come from?
The figures come from UNAIDS estimates, published as part of Access to anti-retroviral drugs, female (%). Statizoid updates them automatically from the source API.

Download this data

CSV · JSON — 25 observations, free to reuse under CC BY 4.0 (World Bank Open Data).

Share, cite or embed this page

Cite this page

Access to anti-retroviral drugs, female in Ecuador. Statizoid, drawing on UNAIDS estimates. Retrieved 07 September 2026, from https://gender.statizoid.com/stat/access-to-anti-retroviral-drugs-female-percent/ecuador/

Embed or link this data

Paste this into a page to link back to these figures. The data itself is free to reuse under CC BY 4.0 (World Bank Open Data); please keep the attribution.

<a href="https://gender.statizoid.com/stat/access-to-anti-retroviral-drugs-female-percent/ecuador/">Access to anti-retroviral drugs, female in Ecuador</a> — Statizoid

About this data

Indicator
Access to anti-retroviral drugs, female (%)
Unit
%
Source
UNAIDS estimates
Licence
CC BY 4.0 (World Bank Open Data)
Coverage
160 places, 3,925 data points, 2000–2024
Last refreshed

The percentage of adult females living with HIV who are receiving antiretroviral therapy.